Xenon Pharmaceuticals announces XEN801 did not meet efficacy endpoints in phase 2 trial
Xenon Pharma reported topline efficacy results from the double-blind, multi-center, vehicle-controlled, parallel-group study designed to evaluate the efficacy, safety, tolerability and systemic exposure of XEN801 for treatment of moderate to severe facial acne.
March 24, 2017